Practice Signal
This review helps pharmacists decide when to start, continue, or stop a statin after 70, weighing STAREE's cardiovascular benefit without a gain in disability-free survival, SAGA/SITE's reassurance on stopping after 75, and each patient's prognosis and goals.
For a robust adult over 70 without cardiovascular disease, atorvastatin 40 mg prevents heart attacks and revascularizations (STAREE: HR 0.70, NNT 37 over about 6 years) but does not preserve independence, cognition or survival. For an adult 75 or older already taking a primary-prevention statin, stopping did not raise 3-year mortality in the only randomized trial (SAGA/SITE), but it brought no symptom or quality-of-life benefit either. Age alone is not a reason to start, stop or withhold a statin; prognosis, function and the patient's goals are.
Until this year, statin decisions in adults over 75 without cardiovascular disease rested on indirect evidence. The Cholesterol Treatment Trialists' individual-patient meta-analysis (28 trials, 186,854 participants, 14,483 over 75) found that each 1 mmol/L LDL-C reduction lowers major vascular events by about 21% at every age, but in primary prevention the benefit looked smaller with age (trend P=0.05), and too few older primary-prevention patients had been randomized to be sure. A VA cohort of 326,981 veterans 75 and older linked statin use to 25% lower all-cause mortality, but that effect was larger than the cardiovascular effect itself, a sign of healthy-user bias rather than drug benefit.
The stopping side was thinner still. The only randomized trial, Kutner 2015, enrolled patients expected to live less than a year: stopping did not meaningfully change 60-day mortality (23.8% vs 20.3%), modestly improved quality of life, and removed about 0.7 other medications. Nothing randomized addressed the far larger group of healthy 75-year-olds taking a statin for primary prevention.
Guidelines reflected that uncertainty. The 2026 ACC/AHA dyslipidemia guideline makes most adults in their 70s statin-eligible and recommends coronary calcium scoring to refine intermediate-risk decisions. The 2026 Canadian deprescribing guideline suggests continuing statins in older adults who are not at the end of life and stopping them for those who are, but its continuation advice rests on very low-certainty observational evidence.
Subscribe to PharmD Signal for the complete evidence synthesis and practice recommendations on every topic, plus every deep analysis we publish.
Become a Subscriber →